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AbsTrACT
Objectives We assessed the prevalence and risk factors 
associated with virological failure among female sex 
workers living with HiV on antiretroviral therapy (art) in 
Kampala, Uganda.
Methods We conducted a cross-sectional study 
between January 2015 and December 2016 using 
routinely collected data at a research clinic providing 
services to women at high risk of Stis including HiV. 
Plasma samples were tested for viral load from HiV-
seropositive women aged ≥18 years who had been on 
art for at least 6 months and had received adherence 
counselling. Samples from women with virological failure 
(≥1000 copies/ml) were tested for HiV drug resistance 
by population-based sequencing. We used logistic 
regression to identify factors associated with virological 
failure.
results Of 584 women, 432 (74%) with a mean age 
of 32 (SD 6.5) were assessed, and 38 (9%) were found 
to have virological failure. HiV resistance testing was 
available for 78% (28/38), of whom 82.1% (23/28) 
had at least one major drug resistance mutation (DrM), 
most frequently M184V (70%, 16/23) and K103n (65%, 
15/23). in multivariable analysis, virological failure was 
associated with participant age 18–24 (adjusted Or 
(aOr)=5.3, 95% ci 1.6 to 17.9), self-reported art non-
adherence (aOr=2.6, 95% ci 1.2 to 5.8) and baseline 
cD4+ t-cell count ≤350 cells/mm3 (aOr=3.1, 95% ci 
1.4 to 7.0).
Conclusions a relatively low prevalence of virological 
failure but high rate of DrM was found in this population 
at high risk of transmission. Younger age, self-reported 
art non-adherence and low cD4+ t-cell count on 
art initiation were associated with increased risk of 
virological failure.
InTrOduCTIOn
With the new focus of ending the AIDS epidemic 
by 2030 and the declaration of the United Nations 
Programme on HIV/AIDS (UNAIDS) 90-90-90 
targets, virological suppression is now a global 
public health priority.1 In 2017, only 52% of adults 
in sub-Saharan Africa (SSA) who were living with 
HIV and on antiretroviral therapy (ART) had 
achieved virological suppression.2 High HIV prev-
alence in SSA particularly among key populations 
including female sex workers (FSWs) poses a major 
challenge to achieving the targets.3 The critical 
factors for improving health outcomes of people 
living with HIV and stopping onward transmission 
are early ART initiation accompanied by sustained 
virological suppression.4 In Uganda, the HIV prev-
alence among FSWs ranges between 33% and 37% 
compared with 9.5% among the general female 
population.5–7
Reports show that an estimated 16% of new 
infections in Uganda may be attributed to FSWs 
and their clients.8 Due to various social issues, 
stigma and discrimination, and criminalisation of 
sex work, FSWs are usually hard to reach, creating 
challenges in providing appropriate HIV care 
services, including early HIV testing, ART initia-
tion, adherence support and HIV plasma viral load 
(VL) monitoring.9 Very good adherence to medi-
cation is required to prevent the development of 
antiretroviral drug resistance, an important goal in 
preserving the benefits of ART at the individual and 
population level.10
Previous research has shown that HIV drug resist-
ance poses a threat to future ART success, particu-
larly in countries where documented HIV prevalence 
in key populations is high.7 In South Africa, 73.7% 
of FSWs and in Rwanda 77.1% of FSWs with viro-
logical failure had at least one major drug resist-
ance mutation (DRM) to either nucleoside reverse 
transcriptase inhibitors (NRTIs) or non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). The 
lamivudine (3TC, an NRTI drug) mutation M184V 
and the efavirenz (EFV) and nevirapine (NVP) (two 
NNRTI drugs) mutations K103N and 181C are 
frequently observed in cases of virological failure.11 12 
Yet combinations of tenofovir (TDF) 3TC and EFV/
NVP are extensively used as a first-line regimen in 
limited resource settings.13 The accumulation of 
mutations against drugs from different drug classes 
and the presence of broad cross-resistance mutations 
will jeopardise the effectiveness of ART care.
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Despite the growing focus on the HIV treatment cascade, there 
is little information about the continuum of care from diagnosis 
to virological suppression among FSWs in SSA. Available data on 
factors associated with VL among FSWs have been from devel-
oped countries14 15 and have shown that virological suppression 
is associated with older age, higher CD4+ T-cell counts and 
good adherence. Furthermore, virological suppression has been 
shown to reduce morbidity and mortality and improve overall 
quality of life as well as economic productivity.16
In 2014, Uganda adopted VL testing guidelines17 as a gold 
standard for monitoring the individual response to ART. 
However, little is known about virological suppression and asso-
ciated factors among FSWs on ART. An understanding of these 
factors is important to guide sustainable long-term strategies for 
ART adherence programmes in this population. In this paper, we 
assess factors associated with virological failure among HIV-pos-
itive FSWs on ART in Kampala, Uganda.
MeThOds
study design, population and setting
From January 2015 to December 2016, we enrolled FSWs living 
with HIV on ART into a cross-sectional study to test for VL. 
The FSWs were recruited from a cohort of women at high risk 
of HIV infection attending the Good Health for Women Project 
(GHWP) clinic. The FSWs coming to the clinic are mobilised 
from ‘sex work hotspots’. We defined female sex work as having 
sex with men in exchange for money, favours or other goods 
either regularly or casually. The GHWP clinic is in a periurban 
suburb in the south of Kampala, the capital city of Uganda. The 
clinic was established in 2008 to study the epidemiology of HIV 
and STIs and to implement HIV/STI prevention among FSWs. 
HIV prevalence in the cohort is 37%7 and the ART acceptance 
rate within 1 month is 28%.18
eligibility criteria
The eligibility criteria for participation in the study included (1) 
being an FSW aged ≥18 years old living with HIV, (2) having 
documented evidence of being on ART for ≥6 months and 
(3) having had VL tested at ≥6 months of being on ART. We 
excluded participants who were not on ART, those enrolled 
within 6 months of starting ART and those who did not have 
data on VL and selected covariates.
The GhWP ArT programme and procedures
The GHWP clinic was accredited by the Ministry of Health 
(MoH) in Uganda to provide ART in January 2013. From 
January 2013 to July 2014, FSWs living with HIV were initiated 
on ART using CD4+ T-cell counts (≤350 cells/mm3) and WHO 
staging criteria. In August 2014, the GHWP clinic started rolling 
out the new test and start ART guidelines,17 with all FSWs living 
with HIV being initiated on ART irrespective of CD4 T-cell 
counts as long as they were willing and ready to start treatment. 
In the same year, in pursuit of meeting the 90-90-90 targets, the 
GHWP clinic, in collaboration with the MoH and the Central 
Public Health Laboratories, initiated VL monitoring and testing. 
A VL test is done every 6–12 months for all patients on ART as 
follows: (1) after 6 months on ART if newly initiated; (2) if VL 
<1000 copies/mL, VL is repeated at 12 months, then every 12 
months thereafter; (3) if VL >1000 copies/mL, three intensive 
adherence counselling (IAC) sessions are done 1 month apart 
and VL is repeated on third IAC session; (4) if VL >1000 copies/
mL, at third IAC session, patients are switched to second-line 
ART or to third-line if already on second line.19
The initial ART prescriptions were for 2 weeks, then 1 month, 
followed by an evaluation to check for any ART reactions, and 
then three monthly refills. First-line ART regimens combined 
two NRTIs (TDF or zidovudine and lamivudine or emtricitabine) 
and one NNRTI (NVP or EFV). Second-line regimens combined 
two NRTIs not used in the first-line regimen with a boosted 
protease inhibitor (PI) (ritonavir-boosted lopinavir). Second-line 
regimens were given to women who failed to respond to a first-
line regimen. IAC was done routinely for women identified with 
virological failure to enhance ART adherence. For those who 
missed appointments, active tracking by the field team and peer 
educators was done through phone calls, SMS (short message 
service) reminders, biweekly peer support group sessions and 
home visiting, and updating clients’ contact details at each clinic 
visit.
Laboratory procedures
As part of routine clinical care, blood samples were collected to 
assess HIV VL and CD4+ T-cell counts. Baseline CD4+ T-cell 
counts on ART initiation and VL were done at least 6 months 
after ART initiation. VL testing was performed on plasma using 
an Abbott RealTime HIV-1 PCR assay (Abbott Park, Illinois, 
USA), whereas CD4+ T-cell counts were performed on whole 
blood using Multiset Trucount tube-lyse no-wash method 
(Becton, Dickinson and Company, San Jose, California, USA). 
Samples from patients with virological failure (≥1000 copies/
mL) were retrieved and submitted for drug resistance testing at 
the Medical Research Council/Uganda Virus Research Institute 
laboratory in Entebbe, Uganda. Briefly, viral RNA was extracted 
from 140 μL of plasma using the QIAamp Viral RNA Mini Kit 
(Qiagen), and the entire protease (codons 1–99) and amino 
terminus of reverse transcriptase (codons 1–320) were amplified 
and sequenced using the ABI 3500 machine (Applied Biosys-
tems).20 Sequences were base-called using Sequencher V.5.2.4 
and DRM was analysed using the Stanford HIVdb program 
(https:// hivdb. stanford. edu/ hivdb/ by- mutations),21 using the 
2009 WHO mutation list. Basic phylogenies were performed to 
determine sequence relatedness and to rule out sample contam-
inations. Viral sequences are available in GenBank (accession 
numbers MH166811–MH166838).
data collection and study measures
Counsellors collected data on sociodemographic characteristics, 
sexual behaviour and relevant ART care history. Data on initial 
WHO staging, place of ART initiation, ART treatment regimen 
given and ART duration were abstracted from the MoH ART 
card and the ART register. Laboratory tests abstracted included 
baseline CD4+ T-cell counts on ART initiation and absolute VL 
at least 6 months after initiating ART.
VL was categorised as virology failure (≥1000 copies/mL) and 
virological suppression (<1000 copies/mL).10 19 The primary 
outcome of this study was virological failure assessed at least 
6 months after initiating ART. Sociodemographic measures 
included age, marital status, education level, alcohol use, sexual 
partner violence in the last 3 months and main source of income. 
Alcohol use was assessed using a standardised WHO Alcohol 
Use Disorders Identification Test.22 Alcohol use was classified 
into three categories: harmless or low risk drinkers, score 1–7; 
harmful or high-risk drinkers, score 8–19; and alcohol-de-
pendent, score 20+. The main source of income was catego-
rised as sex work alone or sex work and other sources of income 
(working in the bar, salon, nightclub and karaoke). Sexual 
behaviour characteristics included the number of lifetime sexual 
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Figure 1 Recruitment profile of female sex workers (FSWs) living with 
HIV on antiretroviral therapy (ART) at Good Health for Women Project 
(GHWP) clinic in Kampala, Uganda (2015–2016). VL, viral load.
partners and condom use at last sexual intercourse with paying 
clients and other partners. Clinical characteristics included base-
line CD4+ T-cell counts, VL at least ≥6 months after ART initi-
ation and adherence level using self-report to prescribed ART 
doses. Adherence was assessed using a self-reported adherence 
method23 where women were asked how many doses they had 
missed in the previous 7 days. The overall individual self-re-
ported adherence was estimated by aggregating the self-reported 
number of missed doses during the 7 days prior to each clinic 
visit divided by the total number of doses expected for all the 
visits attended (aggregated over 7-day periods) expressed as a 
percentage. Non-adherence was defined as taking <95% of the 
prescribed doses in the 7 days prior to all visits completed.19
statistical analyses
Data were double-entered in Microsoft Access, cleaned and 
exported to STATA V.14.0 for analysis. We resolved discrepan-
cies by checking the source documents for clarification. Categor-
ical demographic and clinical characteristics were summarised by 
counts and percentages. Continuous variables were summarised 
by means and SD or medians and IQRs. The proportion with 
virological failure was analysed by the different demographic 
and clinical characteristics. Factors for which the association 
attained statistical significance on log likelihood ratio test (LRT) 
of p<0.20 were selected for the multivariable logistic regression 
model. Logistic regression models were fitted to identify factors 
associated with virological failure at unadjusted analysis. Factors 
were retained in the final multivariable logistics regression model 
if their inclusion did not make the fit of the model significantly 
worse at the 5% level on an LRT.
sensitivity analyses
We conducted sensitivity analyses to address the issue of missing 
data on selected covariates. Participants who had VL results but 
with insufficient data on some covariates were imputed using 
multivariate imputation by chained equations approach. A 
sample of missing values were created, conditional on the distri-
bution of the remaining predictors in the multivariable model. 
We assumed that the data were missing at random and carried 
out 10 rounds of multiple imputations; the final data for anal-
ysis after imputation were combined using Rubin’s rule.24 We 
compared the results from the complete case analysis and those 
from the imputation model.
resuLTs
recruitment profile
During the study period, 603 FSWs living with HIV attended the 
GHWP clinic (figure 1); of these, 171 (28%) were excluded from 
analysis due to ineligibility: 12 (2%) were ART-naive, 7 (1%) 
had been on ART for <6 months, 107 (18%) had no VL results 
(missed appointments (n=100), transferred (n=3), sample not 
collected (n=4)), and 45 (7%) had insufficient data on study 
independent variables. Of the 45 who had insufficient data, 5 
(11%) had virological failure. Thus 432 FSWs were included in 
the analysis (figure 1).
Participant characteristics
The mean age of the FSWs included in the analysis was 32.5 
years (SD±6.5). About half of the FSWs (55%) were aged 25–34 
years, 58% had attained at least primary education, and 66% 
were divorced or separated. About a third had experienced 
physical sexual partner violence in the previous 3 months, 47% 
reported sex work as their main source of income, and 14% of 
FSWs were alcohol-dependent (table 1).
Eighty per cent reported to have had at least 50 lifetime 
sexual partners, 60% reported using condoms during the last 
sexual intercourse, and 60% reported consistent condom use. 
Two-thirds initiated ART at WHO stage I and 9% at stages III 
and IV. Participants’ median duration on ART was 2.3 years 
(IQR, 1.8–3.2) and the median CD4+ T-cell count at baseline 
was 395 cells/mm3 (IQR, 248–597 cells/mm3). The majority 
(98%) were on first-line ART regimen and 83% were >95% 
adherent to their ART treatment. Virological suppression was 
achieved by 394 FSWs (91%) (table 1).
drug resistance mutations
Of the 38 (9%) FSWs who had virological failure, plasma 
samples of 28 (74%) were successfully sequenced, and 23 of 28 
(82%) had at least one major surveillance drug resistance muta-
tions (SDRM). Of the FSWs with at least one major DRM, 21 of 
23 (91%) were on first-line regimen. All had an NNRTI DRM, 
16 (70%) had both NRTI and NNRTI DRM, while 1 patient had 
DRM to all ART drug classes (NRTI: TDF or zidovudine and 
lamivudine or emtricitabine; NNRTI: NVP and EFV; and PI: 
ritonavir-boosted lopinavir). The predominant mutations were 
M184V16 (70%) and K103N 15 (65%). The median duration 
on ART among those with DRM was 3.4 years (IQR, 2.3–6.2). 
We observed a high frequency of thymidine analogue mutation 
(15, 65%) (see table 2).
Virological failure and associated factors
The proportion of FSWs with virological failure increased with 
decreasing age, 18% (18–24 years) vs 6% (>35 years), and was 
higher among non-adherent participants (16%) compared with 
those adherent to ART (7%) (table 3). More FSWs with no 
education had virological failure (15%) compared with FSWs 
with secondary level and above (12%). Compared with FSWs 
with CD4 ≤350 cells/mm3, those with CD4 >350 cells/mm3 
had a lower proportion of virological failure, that is, 6% vs 
13%. Additionally, the proportion with virological failure was 
higher among transfer-in patients (16%) compared with those 
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Table 1 Characteristics of FSWs living with HIV who remained on 
ART for at least 6 months in Kampala, Uganda
Variable Category
Included in the analysis
(n=432), n (col %)
Sociodemographic characteristics
Age category 
  35–54 151 (35)
25–34 237 (55)
18–24 44 (10)
Level of education 
  No education 40 (9)
Primary 251 (58)
Secondary and above 141 (33)
Religion 
  Christian 333 (77)
Muslim 99 (23)
Marital status 
  Married 19 (4)
Widowed 47 (11)
Divorced/Separated 288 (67)
Never married 78 (18)
Source of income 
  Other in addition to sex work 227 (53)
Sex work only 205 (47)
Violence experience in the last 3 months 
  Yes 148 (34)
No 284 (66)
Alcohol use 
  Low risk 188 (44)
Harmful/High risk 182 (42)
Alcohol-dependent 62 (14)
  Sexual behavioural characteristics
Condom use at last sexual intercourse 
  Yes 259 (60)
No 173 (40)
Lifetime sexual partners 
  <50 77 (18)
≥50 345 (80)
Missing 10 (2)
  Participants’ clinical characteristics
Baseline CD4+ T-cell counts 
  ≤350 187 (43)
>350 245 (57)
WHO stage 
  Stage I 265 (61)
Stage II 82 (19)
Stages III and IV 37 (9)
Missing 48 (11)
Place of ART initiation 
  Clinic-initiated 374 (87)
Transfer-in 58 (13)
ART regimen 
  First-line
AZT-3TC-EFV
AZT-3TC-NVP
TDF-3TC-EFV
TDF-3TC-NVP
5 (1)
17 (4)
378 (88)
22 (5)
Second-line
TDF-3TC-LPV/r
TDF-3TC-ATV/r
AZT-3TC-ATV/r
3 (1)
6 (1)
1 (0)
  Adherence status 
  Adherent 359 (83)
Non-adherent 73 (17)
Continued
Variable Category
Included in the analysis
(n=432), n (col %)
  Duration on ART (years) Median (IQR) 2.3 (1.8–3.2)
  Baseline CD4+ T-cell count Median (IQR) 395 (248–597)
Criteria for ART initiation 
  CD4 ≤350 cells/mm3 171 (40)
Test and treat 261 (60)
ART, antiretroviral therapy; ATV/r, Atazanavir/Ritonavir; AZT, zidovudine; EFV, efavirenz; FSWs, female 
sex workers; LPV/r, Lopinavir/Ritonavir; NVP, nevirapine; 3TC, lamivudine; TDF, tenofovir.
Table 1 Continued
Table 2 Type and frequency of drug resistance mutations detected in 
23 samples of HIV-positive FSWs with virological failure who remained 
on ART for at least 6 months
Mutations n (%)
Resistance category (n=28)
  Sequences with any SDRM 23 (82.1)
  PR sequences with any PI SDRM 1 (3.6)
  RT sequences with any NRTI SDRM 16 (57.1)
  RT sequences with any NNRTI SDRM 23 (82.1)
  RT sequences with any NRTI + any NNRTI SDRM 16 (57.1)
  PRRT sequences with any NRTI + any NNRTI + PI SDRM 1 (3.6)
NRTI-related mutations (n=23) 
  M184V 16 (70)
  T215Y 6 (26)
  K65R 3 (13)
  L74V 3 (13)
  M41L 3 (13)
  D67N 2 (9)
  K219Q 2 (9)
  L210W 1 (4)
  K70R 1 (4)
NNRTI-related mutations (n=23) 
  K103N 15 (65)
  G190A 7 (30)
  P225H 6 (26)
  K101E 5 (22)
  Y181C 4 (17)
  V106M 1 (4)
  V179F 1 (4)
  L100I 1 (4)
PI-related mutations (n=23) 
  M46L 1 (4)
ART, antiretroviral therapy; FSWs, female sex workers; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; 
PI, protease inhibitor; PR, Protease; PRRT, Protease and Reverse Transcriptase; RT, 
Reverse Transcriptase; SDRM, surveillance drug resistance mutation.
who initiated ART at GHWP (8%), with borderline statistical 
significance. The proportions of virological failure did not differ 
within the categories of the other FSW characteristics.
In adjusted (multivariable) analysis, virological failure was 
independently associated with participant age 18–24 (adjusted 
OR (aOR)=5.3, 95% CI 1.6 to 17.9), non-adherence (aOR=2.6, 
95% CI 1.2 to 5.8) and low baseline CD4+ T-cell counts (≤350 
cells/mm3) (aOR=3.1, 95% CI 1.4 to 7.0) (table 3).
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Table 3 Characteristics of HIV-positive FSWs and association with virological failure in Kampala, Uganda (n=432)
Variable suppressed, n (col %) not suppressed, n (col %) Or (95% CI) LrT p value aOr (95% CI)
Age category, years 0.064
  35–54 142 (36)  9 (24) 1 1
  25–34 216 (55) 21 (55) 1.5 (0.7 to 3.4) 1.9 (0.8 to 4.7)
  18–24 36 (9)  8 (21) 3.5 (1.3 to 9.7) 5.3 (1.6 to 17.9)
Level of education 0.048
  No education* 34 (9)  6 (16) 1 1
  Primary 236 (60) 15 (39) 0.4 (0.1 to 1.0) 0.4 (0.1 to 1.1)
  Secondary and above 124 (31) 17 (45) 0.8 (0.3 to 2.1) 0.9 (0.3 to 2.5)
Religion
  Christian* 304 (77) 29 (76) 1
  Muslim 90 (23)  9 (24) 0.9 (0.4 to 2.1)
Source of income 0.091
  Others in addition to sex work 212 (54) 15 (39) 1 1
  Sex work only 182 (46) 23 (61) 1.8 (0.9 to 3.5) 1.6 (0.8 to 3.4)
Marital status
  Never married 69 (18)  9 (24) 1 0.361
  Married 325 (82) 29 (76) 0.7 (0.3 to 1.5)
Physical violence with sexual partners in the past 3 
months
  No* 137 (37) 11 (29) 1 0.464
  Yes 257 (65) 27 (71) 0.8 (0.4 to 1.6)
Alcohol use
  Harmful/High risk 338 (86) 32 (84) 1
  Alcohol-dependent 56 (14)  6 (16) 1.1 (0.5 to 2.8)
Condom use at last sexual intercourse
  Yes* 236 (60) 23 (61) 1 0.94
  No 158 (40) 15 (39) 1.0 (0.5 to 1.9)
Baseline CD4+ T-cell counts
  >350 cells/mm3 231 (59) 14 (37) 1 0.01 1
  ≤350 cells/mm3 163 (41) 24 (63) 2.4 (1.2 to 4.8) 3.1 (1.4 to 7.0)
Place of ART initiation 0.072
  Clinic-initiated* 345 (88) 29 (76) 1 1
  Transfer-in 49 (12)  9 (24) 2.2 (1.0 to 4.9) 1.7 (0.5 to 5.9)
Adherence status 0.019
  Adherent* 333 (85) 26 (69) 1 1
  Non-adherent 61 (15) 12 (31) 2.5 (1.2 to 5.3) 2.6 (1.2 to 5.8)
  Duration of ART (in years), median (IQR) 2.3 (1.8–3.1)  2.7 (2.2–3.8) 1.2 (1.0 to 1.4) 0.071 1.1 (0.8 to 1.4)
For the values in bold; Statistically significant(p<0.05) ; For Multivariate analysis, we retained variables with LRTp-value less than 0.20 and common confounders (age).
*Reference category.
aOR, adjusted OR.ART, antiretroviral therapy; FSWs, female sex workers; LRT, likelihood ratio test;
sensitivity analysis results
A sensitivity analysis by imputing data for participants missing 
other covariates but having VL data was conducted, and the 
results were similar to when they were excluded.
dIsCussIOn
We found that the proportion of FSWs with virological failure 
was relatively low. These encouraging results are almost similar 
to the results from another study in Malawi among FSWs25 and 
those from the Ugandan general population,26 although this was 
lower than the virological results of a study among Zimbabwean 
FSWs.27 The high level of virological suppression in this popu-
lation highlights good progress as we move towards reaching 
the 90-90-90 target introduced by UNAIDS in 2014.1 Our study 
was conducted in a clinical research setting with free care, with 
IAC and active follow-up of participants. Thus, this may explain 
the relatively high levels of adherence observed in this study, 
which may have contributed to the lower virological failure, 
even though some reporting bias may have occurred. One study 
in Benin among a cohort of FSWs found that higher VL was 
attributed to lower reported adherence.28 Good adherence with 
the goal of virological suppression is critical to improving health 
outcomes and onward transmission.29
We found that FSWs with virological failure had high rates 
of DRM. Our findings were within similar ranges to those from 
Uganda30 in the general population and South Africa among 
FSWs.11 It is possible that this high level of drug resistance could 
have been a result of non-adherence. Poor adherence has been 
shown to be a major cause of virological failure with a poten-
tial risk of drug resistance (W1). However, due to relatively 
short average ART time, we cannot exclude that some of these 
mutations were already present at baseline. However, given the 
multiple sexual relationships and inconsistent condom use in 
this population, our major concern is that there may be some 
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alarming rates of DRM being transmitted between clients or 
regular partners and FSWs. This highlights the importance of 
monitoring of VL and drug resistance within FSW programmes 
and the urgent need to understand the DRM transmission 
dynamics and the outcomes.
Furthermore, consistent with findings from Rwanda,12 the 
most predominant mutations observed in this study were 
M184V for NRTI and K103N for NNRTIs. This finding reflects 
high-level resistance to lamivudine, NVP and EFV, which are 
the backbone ART drugs in this setting. The combination of 
TDF+3TC+EFV/NVP/dolutegravir is extensively used as a first-
line regimen which greatly limits treatment choices in our ART 
programme.
Young age was independently associated with virological 
failure in our study. This is consistent with other studies (27, W2) 
conducted among FSWs in SSA. These findings have also been 
demonstrated in Uganda in the general population.26 In Uganda, 
young people face numerous challenges, including social, 
economic, cultural and treatment-related challenges, which may 
contribute to the higher rates of non-adherence (W3). However, 
our results contradict with the results from a study in Canada 
among FSWs which did not find an association with age (W4). 
This difference in findings could be related to the diversity in the 
age ranges used in that study and the sociocultural factors that 
vary across populations.
We demonstrated that having virological failure was signifi-
cantly associated with non-adherence and low CD4+ T-cell 
counts. This is consistent with the results from Burkina Faso, 
where FSWs with reported lower adherence had lower CD4 
gains, higher virological failure and a higher mortality rate 
compared with the general population (W2). Research from our 
cohort has shown that these FSWs are often exposed to high 
levels of alcohol use and partner violence, which impact on their 
ability to adhere to treatment (W5). A systematic review among 
FSWs also reported that not being at home to take pills and 
potential loss of clients if seen taking ART during work hours 
were factors that prevented them from adhering to treatment 
(W6). It is therefore important that HIV interventions and ART 
programmes for FSWs try to address the structural and social 
barriers to HIV treatment that FSWs face.
Our study had some limitations. First, 18% of FSWs had no VL 
test results mainly due to missed clinic appointments. This could 
have reduced the power to detect more associations with viro-
logical suppression. We observed significant differences between 
the women with VL data and those without, suggesting that there 
may be a selection bias; it is not known whether those who missed 
appointments are at risk of not being suppressed virally. Second, 
while we observed that 98% of FSWs living with HIV more than 
6 months postreferral and linkage into ART care were on ART, 
our study was designed to report virological suppression. We 
did not assess the HIV test status of FSWs and thus do not have 
adequate data on the full HIV treatment cascade to characterise the 
90-90-90 targets. Third, our findings may not represent virolog-
ical suppression rates of FSWs in other clinic settings in Kampala 
because the study was conducted in only one clinic and may not 
be generalisable to places with limited access to HIV care services. 
Lastly, because we do not have SDRM data on those with virolog-
ical failure, we were unable to compare control by mutation status.
In summary, we found a relatively low prevalence of virological 
failure among FSWs, but this is accompanied by a high propor-
tion of DRMs among women with virological failure. Younger 
age, non-adherence and low CD4+ T-cell counts (≤350 cells/
mm3) at baseline assessment were associated with an increased 
risk of virological failure at 6 months.
Key messages
 ► Given the high virological suppression in this population, 
strategies that enhance the 90-90-90 targets among female 
sex workers (FSWs) are needed to maximise the benefits of 
antiretroviral therapy.
 ► Considering the significant association between young age 
and virological failure, interventions targeting young FSWs to 
improve virological suppression should be developed.
 ► Given the high rate of drug resistance mutation (DRM), there 
is a need for research to monitor the transmission dynamics 
of DRM and its impact on treatment success among FSWs.
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